FOX CHASE CANCER CENTER
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1904-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.foxchase.org
Liver Cancer Community Education
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 67
- Registration Number
- NCT04272619
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Clinician Communication About Sexual Health
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04262219
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04055753
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT04037072
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Utility of CAML as Diagnostic for Early Stage Lung Cancer
Active, not recruiting
- Conditions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT03992183
- Locations
- ๐บ๐ธ
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Coping Together After Breast Cancer
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 240
- Registration Number
- NCT03930797
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 117
- Registration Number
- NCT03786692
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Palliative and Oncology Care Intervention: Symptom COACH
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT03760471
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT03719898
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 153
- Registration Number
- NCT03624972
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath